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Background: Gestational Diabetes Mellitus (GDM) has well recognised adverse health implications for the mother
and her newborn that are both short and long term. Obesity is a significant risk factor for developing GDM and the
prevalence of obesity is increasing globally. It is a matter of public health importance that clinicians have evidence
based strategies to inform practice and currently there is insufficient evidence regarding the impact of dietary and
lifestyle interventions on improving maternal and newborn outcomes. The primary aim of this study is to measure
the impact of a telephone based intervention that promotes positive lifestyle modifications on the incidence of
GDM. Secondary aims include: the impact on gestational weight gain; large for gestational age babies; differences
in blood glucose levels taken at the Oral Glucose Tolerance Test (OGTT) and selected factors relating to self-efficacy
and psychological wellbeing.
Method/design: A randomised controlled trial (RCT) will be conducted involving pregnant women who are
overweight (BMI >25 to 29.9 k/gm2) or obese (BMI >30 kgm/2), less than 14 weeks gestation and recruited from the
Barwon South West region of Victoria, Australia. From recruitment until birth, women in the intervention group will
receive a program informed by the Theory of Self-efficacy and employing Motivational Interviewing. Brief ( less than
5 minute) phone contact will alternate with a text message/email and will involve goal setting, behaviour change
reinforcement with weekly weighing and charting, and the provision of health information. Those in the control
group will receive usual care. Data for primary and secondary outcomes will be collected from medical record
review and a questionnaire at 36 weeks gestation.
Discussion: Evidence based strategies that reduce the incidence of GDM are a priority for contemporary maternity
care. Changing health behaviours is a complex undertaking and trialling a composite intervention that can be
adopted in various primary health settings is required so women can be accessed as early in pregnancy as possible.
Using a sound theoretical base to inform such an intervention will add depth to our understanding of this
approach and to the interpretation of results, contributing to the evidence base for practice and policy.
Trial registration: This trial is registered with the Australian New Zealand Clinical Trials Registry (ANZCTR):
ACTRN12613000125729.
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The prevalence of Gestational Diabetes Mellitus (GDM)
in Australia has been reported ranging from 1.7 to 9.6%
[1-4] and it has been associated with significant rates of
maternal and perinatal complications. Being overweight
(a body mass index (BMI) of >25 kg/m2) or obese (BMI
of >30 kg/m2) are recognised risk factors for developing
GDM in pregnancy [5-8] and confer a 1.3 to 4.8 in-
creased likelihood of developing this condition [6,8].
Maternal complications of GDM include an increased
risk of developing Type 2 diabetes, metabolic syndrome
and cardiovascular disease [5,9,10]. Newborns of preg-
nancies affected by GDM are at risk of macrosomia,
shoulder dystocia, birth injuries and hypoglycaemia
[11-13]; as young children they are at risk of becoming
overweight, and in adolescence of impaired glucose tol-
erance and obesity [14].
In addition to developing GDM, women who are obese
are at increased risk of many pregnancy related conditions
including miscarriage, pre-eclampsia, hypertension, infec-
tion and thromboembolic disease [11,15-17] and have a
greater chance of caesarean section [11,15,16,18-21], in-
duction of labour [15,16,18,21] and death related to child-
bearing [11,19,21-23].
Compared to babies of women in a normal weight
range, babies of overweight and obese women are more
likely to be macrosomic [12,15,16,22,24], preterm
[11-13,16,25], have a congenital anomaly [11-13,24], be
admitted to the neonatal intensive care unit [11-13,25]
and need treatment for jaundice or hypoglycaemia
[11,16,17]. Thus, GDM particularly for those overweight
and obese, increases both short and long term risks to
the health of both the woman and her baby.
Over a third of pregnant women in Australia are either
overweight or obese [2,6,11] and prevalence is higher in
rural and regional areas than in metropolitan areas
[6,26]; a prevalence of overweight and obesity of 65.5%
has recently been reported in the pregnant population of
north-east Victoria [6]. The rates of obesity are also in-
creasing internationally [27] and identification of evi-
dence based strategies to reduce the incidence of GDM
and promote more healthy lifestyle choices in women
who are overweight and obese needs to be prioritised to
inform practice and health policy.
Healthy weight management for overweight and obese
women includes avoiding excessive weight gain [28] and
ideally aligning gestational weight gain to recommended
ranges based on BMI [29-31]. However, intervention
studies [32-35] have reported only a third to a half of
obese women achieve a gestational weight gain within
the recommended range [36,37]. Furthermore, there is
limited evidence to support the effectiveness of dietary
and physical activity lifestyle interventions in preventing
adverse perinatal outcomes for obese women. In asystematic review of nine trials involving 743 women,
Dodd and colleagues [38] concluded that the effective-
ness of lifestyle interventions in pregnancy remains
unclear. This is of significant concern and forms the ra-
tionale for trialling a different approach to preventing
excessive weight gain in obese women.
There is a paucity of robust evidence to guide practice,
with a limited number of published randomised con-
trolled trials that have tested interventions with preven-
tion of GDM as the primary outcome [39-41]. One of
these trials [40], tested the effectiveness of a composite
intervention versus usual care in preventing GDM. The
intervention incorporated elements of continuity of care,
measuring weight gain at each clinic visit, a regular five
minute visit with a food technologist and a session with
a clinical psychologist. The researchers concluded that
the repetition of the intervention contributed to the
positive outcomes. However, the intensive nature of the
intervention, with a reliance on specialised staff, raises
concerns regarding accessibility and sustainability in low
socioeconomic status (SES) settings particularly rural
and regional health care services.
Based on the approach of Social Cognitive Theory [42]
and using the principles of Motivational Interviewing
[43] we have developed a composite intervention that
employs continuity of contact through weekly communi-
cation with the participating pregnant woman. The
EDGE intervention (Educate, Develop Goals, Engage)
modifies elements of Quinlivan et al. [40], specifically
continuity of contact and reinforcement of behaviour
modifications, and applies these to a format that can be
trialled in areas of low SES and more broadly. The
EDGE program will commence at recruitment and con-
tinue until birth.
We propose to explore the effectiveness of the EDGE
intervention compared to usual care, in preventing the
incidence of GDM in overweight and obese women. The
results of this trial will contribute to our understanding
of how to effectively facilitate healthy gestational weight
gain in pregnancy, particularly in areas where there are
issues of access to health care resources.
Methods
This study will be conducted in the primary care setting
of Barwon South West, Victoria, Australia. A RCT
design will be employed where pregnant women will be
individually randomised and allocated to either the inter-
vention or a control group. The study will be conducted
and reported using the CONSORT recommendations
[44] (Additional file 1).
Aims
The primary aim of this trial is to measure the impact of
the EDGE intervention compared to usual care on the
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primary hypothesis is that women randomised to the
EDGE intervention will have 10% fewer diagnoses of
GDM than women in the control group. There are four
secondary aims: to measure the impact of the EDGE inter-
vention compared to usual care on 1) restricting gesta-
tional weight gain to the weight ranges recommended by
the Institute of Medicine [29]; 2) reducing the incidence of
babies born large for gestational age (LGA); 3) differences
in blood glucose levels taken at the Oral Glucose Toler-
ance Test (OGTT) and 4) promoting self-efficacy and se-
lected factors for psychological well-being.Participants
Inclusion criteria: women with a singleton pregnancy
will be included if their gestation is less than 14 weeks
and their BMI ≥25. Exclusion criteria will include
women: with pre-existing diabetes (types 1 and 2), a
past history of gestational diabetes, unable to give
informed consent in English, currently experiencing
vaginal bleeding or with severe medical conditions pre-
venting them from being able to undertake regular low
impact exercise.
Recruitment strategies
Women will be recruited from 30 participating general
practices within the rural and regional area surrounding
Geelong, Victoria. All women who meet the selection
criteria will be informed of the study by the general
practitioner (GP) or Practice Nurse (PN). Women inter-
ested in participating will be provided with a Participant
Information and Consent Form and the GP/PN will ob-
tain written informed consent and complete an enrol-
ment form; both documents will be forwarded to the
research office. All women enrolled in the trial will be
given a study pack by the recruiting GP/PN that con-
tains the first questionnaire with a reply paid envelope
and a copy of the consent form.
Randomisation procedure
A computer generated randomisation sequence will be
used to facilitate the block randomisation of participants.
Upon receipt of the consent and enrolment form by the
research office, random allocation to the intervention or
control group will be conducted by an individual who is
independent to the study by drawing opaque numbered
envelopes consecutively, to reveal the group allocation.
All women will receive written health information: 1)
following recruitment and a reminder/thank-you for
returning the questionnaire (Additional file 2) and 2)
with a reminder/thank-you for returning the second
questionnaire (Additional file 3). Both resources are used
in clinical practice and are readily available.Women allocated to the intervention group will receive
the EDGE program from recruitment until birth,
consisting of weekly contact with a brief (five minute)
phone call each fortnight that employs Motivational
Interviewing techniques on topics such as: identifying bar-
riers and facilitators to positive behaviour change; encour-
aging goal setting; reinforcing positive lifestyle change;
promoting self-monitoring and charting of weight gain
and reflecting on behaviour change. The phone will alter-
nate each week with text message/email contact to engage,
support and reinforce behaviour change.
Women in the control group will receive usual care.
Usual care in this setting involves initial weighing to
calculate BMI [30]. There will be no change to clinical
care beyond the ascertainment of weight from 36 weeks.
A reminder regarding weighing will be sent to all
women with the second questionnaire.Blinding
All participating women will provide written consent
prior to randomisation however women will not be
blinded to allocation. Due to the type of intervention,
blinding of the researchers to allocation is also not real-
istic. Analysis will be performed by a person independ-
ent to the research team to avoid assessment bias.
Primary outcome and measures
Gestational diabetes
The primary outcome is the proportion of women di-
agnosed with GDM between 24 – 28 weeks and will be
defined using both the Australasian Diabetes in Preg-
nancy Society (ADIPS) management guidelines and the
International Association of Diabetes and Pregnancy
Study Groups (IADPSG) criteria. The use of different
measures reflects the current controversy that exists in
practice [3] and both measures will be reported.
Both ADIPS and IADPSG use a 75 gram glucose
load. Using ADIPS criteria, GDM is diagnosed with a
fasting plasma glucose level ≥5.5 mmol/L or a 2 hour
level ≥8.0 mmol/L [45]. The IADPSG criteria diagnose
GDM if any of the following levels are reported: a
fasting plasma glucose level ≥5.1 mmol/L; a 1 hour
level ≥10 mmol/L or a 2 hour level ≥8.5 mmol/L [46].
Secondary outcomes and measures
Gestational weight gain
Differences in the proportions of women with gestational
weight gain within the IOM (Institute of Medicine) guide-
lines [29] will be compared. Weight gain will be calculated
as the difference between the booking-in weight and the
last recorded weight from 36 weeks gestation to birth, as
recorded in the pregnancy care records. IOM guidelines
recommend women with BMI ≥25 to 29.9 kg/m2
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BMI ≥30 kg/m2 (obese) gain 5–9 kilograms [29].
Large for gestational age (LGA) infants
The differences in the proportions of babies that are LGA
will be compared. LGA infants will be defined in keeping
with other trials [38] as a birth weight ≥90th centile for
gender and gestation, as well as a birth weight > 4000
grams. These data will be obtained from a review of med-
ical records and will be reported using both criteria.
Psychological health
Validated scales, where available, will be used to measure
self- reported psychological wellbeing and engagement
in behaviour change: anxiety; depression; self- efficacy
and readiness to change behaviour will be measured at
enrolment and at 36 weeks gestation using question-
naires in hard copy.
Anxiety
Anxiety will be measured using the short version of the
Speilberger State-Trait anxiety inventory (STAI-State)
[47]. Respondents use a four point scale for six items to
indicate how they feel now (1 = Not at all to 4 = Very
much). With reversing of specific responses, mean
scores are reported and higher scores indicate greater
anxiety.
Depression
Depression will be measured using the Beck Depression
Inventory II [48] a 21 item scale with respondents
selecting from one of four statements. Each response is
assigned a score of 0 to 3 and the total score is the sum
of all responses. This scale has been validated to use in
pregnancy; a cut off >16 affords a sensitivity of 0.83, a
specificity of 0.89, positive predicted value of 0.50 and
negative predictive value of 0.98 PPV [49]. The mean
differences between groups will be compared.
Self-efficacy
Self-efficacy related to healthy lifestyle changes in diet
and exercise will be measured and the mean differences
between groups will be compared. Self-efficacy related
to eating will be measured using a 20 item, 10 point
scale ranging from 0 (not confident) to 9 (very
confident) [50]. Sub-scales of the Weight Efficacy Life-
Style Questionnaire include: negative emotions, avail-
ability, social pressure physical discomfort and positive
activities; the total score is the sum of all items. The
Cronbach alpha coefficients of internal consistency
ranged from 0.70 for positive activities to 0.90 for social
pressure [50].
The Self-Efficacy for Exercise Scale will also be used
and consists of nine items that respondents score from 0(not confident) to 10 (very confident) [51]. The Cronbach
alpha coefficient of internal consistency is 0.92 and reli-
ability using the squared multiple correlation coefficient
ranged from 0.38 to 0.76 [51].
Readiness to change
Readiness to change, the importance of change and confi-
dence in changing will be measured using the Readiness
to Change Questionnaire [52] which researchers have
modified for the weight loss context. This scale measures
stages of change (pre-contemplation, contemplation and
active) using 12 items each with a five point rating scale
from 1 (strongly agree) to 5 (strongly disagree). Informa-
tion from this scale will be used descriptively.
Differences in plasma glucose levels
Differences in mean values of fasting, 1 hour and 2 hour
plasma glucose levels from the OGTT will be compared
using both ADIPS and IADPSG criteria in both groups.
Economic evaluation
Resource use data will be collected from medical records
and projections of health cost savings will be informed
by pregnancy and birth outcome data.
Power, sample size and retention
The primary outcome is the proportion of overweight
and obese women diagnosed with GDM. The proportion
of obese women diagnosed with GDM is 17% in a
Victorian context [40]; a difference 10% effect size is con-
sidered clinically significant. It is estimated that 370
women are required (185 per study arm) in order to detect
a difference of 10% between groups with 80% power at a
0.05 level of significance. With an approximate expected
participation of 77% [53] and attrition rate of 15% [53] the
required sample of 370 women will be recruited.
Data collection
A record review from the local hospitals will be
conducted after birth to provide data for GDM and ges-
tational weight gain outcomes. Socio-demographic data,
pregnancy and birth data will be collected from the
medical records and used descriptively to interpret find-
ings. Data will also be obtained from medical records of
General Practices if required.
Self-reported baseline and outcome data will be col-
lected using a paper based questionnaire. The initial
questionnaire will be provided at recruitment and the
second questionnaire will be posted at 36 weeks; reply-
paid envelopes will be provided for both questionnaires.
Ethics
Ethics approval to conduct this study has been provided
by the Human Research Ethics Committee (HREC) of
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endorsed by Deakin University HREC.
Analyses
Initial analysis will examine baseline characteristics of all
women, as an indication that the treatment groups were
comparable for selected variables including, age, parity
and BMI category. Primary and secondary outcomes will
be analysed on an "intention to treat" basis. Differences
between trial arms will use the Chi-squared statistic for
categorical outcomes and Student’s t-test for continuous
outcomes and 95% confidence intervals will be reported.
Appropriate regression models will be employed con-
trolling for co-variants. The fidelity of the intervention
will be assessed and reported and the feasibility of the inter-
vention will be considered in the process evaluation that
will include the experience of participants and GP/PNs.
Discussion
GDM is a condition that can impact on the short-term
and long term health of both the mother and her baby.
The risk factor of obesity is a significant contributor for
this condition and the prevalence of obesity, particularly
in low SES environments, is increasing. To date there is
a lack of evidence to inform practice and policy to
reduce the incidence of GDM and gestational weight
gain so that birth outcomes are optimised. The findings
of this study will inform an area of practice that is of
international significance; trialling an intervention that
has the potential to be sustainable in the primary care
setting and may have broad application.
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